What a Year of Migraine Data Is Teaching Plans About a Category They Thought They Understood

Key Takeaway: As CGRP use and migraine drug costs rise, standard prior authorization rules may not consistently improve outcomes or spending. Plans need a strategy grounded in real utilization patterns and the individualized nature of migraine treatment.

Migraine affects roughly 39 million Americans — about one in eight — making it one of the most common and most disabling conditions in any covered population. For plans and employers, it’s a quiet but significant driver of both healthcare utilization and lost productivity. It also has a way of defying the logic that pharmacy benefits are built around.

One member fills a preventive medication only a few times a year, even though it was prescribed to make migraines less frequent. Another shows up every month for a rescue treatment — the kind taken in the middle of an attack — without ever having tried prevention at all. A third relies on both, month after month, because for some people, stability is not found in the textbook sequence of care, but in the exact combination that keeps the next migraine from swallowing the week.

All three patterns are real. All three can be clinically defensible. And none of them fit neatly to the kinds of utilization controls that have worked in more predictable drug categories.

That's the complexity migraine treatment now poses for plans: not because the condition is new, but because the path to meaningful cost-containment is often far less predictable than benefit design assumes.

Why CGRP Migraine Drug Costs Are Rising — And What Changed in 2024

CGRP medications — calcitonin gene-related peptide inhibitors — have been on the market since 2018. But for much of that time, they remained more promise than routine practice. For patients with chronic migraine, these therapies offered meaningful relief. Still, clinical guidance reserved them for later use, after more traditional and less expensive options had already been tried and failed.

That changed in 2024, when the American Headache Society elevated CGRPs to first-line treatment for patients with chronic migraine. It was more than a clinical update. It marked a shift in how the category would be viewed, and prescribing patterns didn't take long to follow.

We now have a full year of CGRP utilization data — the first year in which volume was substantial enough to reveal clear patterns rather than isolated movement. What that data shows reflects a market-wide shift that no benefit design has been immune to.

Across client groups, CGRP utilization and plan spend increased by nearly 50% — part of a broader market acceleration that IQVIA identified as making migraine one of the fastest-growing drug categories in the U.S. The number of members using these therapies rose by 20%, while PMPM costs increased 31%. Some products moved even faster: Ubrelvy® utilization rose 80.1%, and Emgality® increased 62.8%. These aren't the numbers of a niche category. They reflect a space that has moved faster than most benefit designs were built to handle.

Why Standard Prior Authorization Isn't Controlling CGRP Spend

The most important finding wasn't that utilization increased. It was that the category became harder to manage with the kinds of rules plans often rely on by default.

A year of paid and rejected claims made that clear. Traditional formulary and benefit controls didn't consistently shape utilization in the clean, predictable way they might in a category with more stable prescribing patterns. The rules were there — but the outcomes weren't always as tidy as benefit design would suggest.

Part of the reason is that migraine treatment is deeply individualized. Chronic migraine doesn't follow the more linear clinical pathways seen in hypertension or diabetes, where sequencing tends to be clearer and the next step easier to anticipate. In migraine, a preventive agent and a rescue medication can serve very different roles depending on the patient. A regimen that looks irregular on paper may, in real life, be the only thing that keeps someone functional.

That matters because when a category is this individualized, standard utilization controls don’t always separate inappropriate use from treatment that's simply unconventional. And when a member with real clinical need runs into that mismatch, demand doesn't disappear. It reappears elsewhere: in appeals, prior authorization queues, case review, call center volume, and repeated attempts to secure access through a different channel.

What looks like a safeguard in the benefit can become a steady stream of operational work that does little to improve care and doesn't always produce meaningful savings. Poorly calibrated controls don't just slow utilization. In the wrong category, they can displace it, shifting cost from the pharmacy line into the less visible burden of administration, review, and member therapy disruption.

What an Effective CGRP Management Strategy Actually Requires

The right question for plans isn't how to clamp down harder. It's how to make sure benefit design reflects the population they actually have.

That begins with a closer read of utilization. Not every high-cost pattern is a problem to solve. Not every rejection is evidence that a control is working. And not every unusual regimen represents misaligned care. Sometimes the better opportunity isn't a stricter rule — it's easing access to therapies that are already cost-neutral or lower cost, and reserving plan protections for the places where they can more meaningfully support both clinical appropriateness and financial discipline.

At PharmPix, that means stepping back far enough to see the whole picture: clinical implications, member disruption, short- and long-term consequences, and the financial tradeoffs that don't always show up in a utilization report. It means using data not simply to identify where claims are being paid, but to understand where the current design is supporting members, where therapy disruption is accumulating, and where better alignment is actually possible.

The Question Every Plan Should Be Asking Their PBM About Migraine

For plans, migraine is a useful test of a broader question: is your PBM strategy built on real utilization patterns, or on assumptions about how members should behave?

A PBM that's only processing claims will see rising spend and rising utilization. A PBM managing the category well will ask something harder: where is the current design creating unnecessary barriers, which controls are generating work without clear clinical or financial return, and how can benefit design evolve without destabilizing members who are already on a regimen that works?

The data now exists to make those distinctions. The plans that manage this category best won't be the ones that react to rising spend with blunt controls. They'll be the ones that use real utilization evidence to design a benefit that's actually built for the population in front of them.

FAQs

Why are CGRP migraine drug costs rising?

CGRP therapies are now considered first-line options for many patients with chronic migraine, expanding their use and increasing plan spend in a fast-growing pharmacy category.

How should health plans manage rising CGRP migraine drug costs?

Plans should review actual utilization patterns, distinguish clinically appropriate treatment from misuse and ensure benefit controls support both access and financial discipline.

Why might prior authorization not work well for CGRP medications?

Migraine treatment is highly individualized. A regimen that looks unusual in claims data may be clinically appropriate, and poorly calibrated controls can create member disruption and administrative burden without meaningful savings.